Sunday, November 26, 2006 8:40:43 AM
>>> Ampakines Alleviate Respiratory Depression in Rats.Ren J, Poon BY, Tang Y, Funk GD, Greer JJ.
Department of Physiology, Division of Neuroscience, University of Alberta, Edmonton, Alberta, Canada.
Rationale: There is a need for improved therapeutic interventions to treat both drug- and sleep-induced respiratory depression. Increased understanding of the neurochemical control of respiration will help identify a basis for advances. Activation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors positively modulates respiratory drive and rhythmogenesis in several brain regions including the preBotzinger complex. Ampakines are a diverse group of small molecules that activate subsets of these receptors. Objective: We determined whether the ampakine CX546 would enhance respiratory drive and rhythmogenesis across various stages of development and whether this ampakine could counter opioid- and barbiturate-induced respiratory depression. Methods: Respiratory frequency and amplitude were measured using the following rat models; i) perinatal in vitro brainstem-spinal cord, ii) neonatal in vitro medullary slice, iii) juvenile in situ perfused, working heart-brainstem preparation and, iv) newborn and adult in vivo. Results: The administration of CX546 stimulated baseline respiratory frequency in perinatal in vitro preparations but not older animals (>postnatal day 0). Further, pharmacological depression of respiratory frequency and amplitude was countered at all ages studied by the administration of CX546 in vitro, in situ and in vivo. Significantly, CX546 countered opioid-induced breathing depression in all preparations, without altering suppressing analgesia as assessed by measuring the time to foot withdrawal in response to a thermal stimulus. Conclusions: CX546 effectively reverses opioid- and barbituate-induced respiratory depression without reversing analgesic response. These studies suggest that ampakines may be useful in preventing or reversing opioid-induced respiratory depression and identify a potential for ampakines for alleviating other forms of respiratory depression including sedative use and sleep apnea. <<<
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM